Ba/F3 cells and their use in kinase drug discovery
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purpose of review Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems. Recent findings Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding. Summary Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Cited by
Items 201–268 of 268
Ribeiro, R. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-25042018-161724
Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC
Recondo, G. (2019) · theses.fr (ABES) · doi:10.70675/91dc4b74zbf5dz4c5dza4ebz4c4d02511d76
Investigating the Role of ZNF384 Rearrangements in Acute Leukemia
Dickerson, K. M. (2021) · doi:10.21007/etd.cghs.2021.0528
Mitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-594302/v1
Fernandes, J. C. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-08092021-135736
Toker, A., & Brown, K. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717963691.793465580
Hernandez‐Davies, J. E., Zape, J. P., Landaw, E. M., Tan, X., Presnell, A., Griffith, D., Heinrich, M. C., Glaser, K. B., & Sakamoto, K. M. (2023) · doi:10.1158/1535-7163.c.6535200.v1
Keddy, C., Shinde, P., Jones, K. L., Kaech, S., Somwar, R., Shinde, U. P., & Davare, M. A. (2023) · doi:10.1158/1535-7163.22522824
The growth of ETV6-NTRK3 harbouring cells was inhibited by Artemisia vulgaris L. crude extract
Thanh, H., Tram, V. N., Quan, N. D. T., & Lý, B. T. K. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00631
Proteomic and functional deregulations in Philadelphia negative Myeloproliferative Neoplasms
Socoro-Yuste, N. (2015) · theses.fr (ABES) · doi:10.70675/c40aa343zca4dz4f6az9fbbzd01bb8e41655
“They have already been proved for the study of multiple kinases such as NPM-Alk, Flt3 mutants and JAK2 (196).”
BackgroundDecroocq, J. (2019) · theses.fr (ABES) · doi:10.70675/6e933875z3629z4e49z9d73z698f1f919e4c
Chen, X., & Leyendecker, S. (2024) · Molecular Informatics · doi:10.1002/minf.202300250
Estevam, G. O., Linossi, E. M., Macdonald, C. B., Espinoza, C. A., Michaud, J. M., Coyote‐Maestas, W., Collisson, E. A., Jura, N., & Fraser, J. S. (2024) · eLife · doi:10.7554/elife.91619.2.sa2
Estevam, G. O., Linossi, E. M., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote‐Maestas, W., Pimentel, H., Collisson, E. A., et al. (2024) · eLife · doi:10.7554/elife.101882.1
Yu, Y., Li, N., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1435357
Estevam, G. O., Linossi, E. M., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote‐Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882.2 · Cited by 1
Estevam, G. O., Linossi, E. M., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote‐Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882.3.sa3
Shared and distinct sequence-function signatures define different modes of human TpoR activationPreprint
Wu, X., McLeod, H., Malinovitch, A., Hunter, S. M., Ramesh, S., Go, M., Nguyen, J. V., Rubin, A. F., Bürger, W., Blombery, P. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.675271
Zhao, Y., He, C., Zhang, D., Guo, Y., Peng, Z., Yu, L., Li, N., Chen, C., Zhao, Z. J., & Chen, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22606892
Liu, C., Jiao, B., Wang, P., Zhang, B., Gao, J., Li, D., Xie, X., Yao, Y., Yan, L., Qin, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25150584
Miyanaga, A., Matsumoto, M., Beck, J. A., Horikawa, I., Oike, T., Okayama, H., Tanaka, H., Burkett, S. S., Robles, A. I., Khan, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14299290
Liu, C., Jiao, B., Wang, P., Zhang, B., Gao, J., Li, D., Xie, X., Yao, Y., Yan, L., Qin, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25150734
Liu, C., Jiao, B., Wang, P., Zhang, B., Gao, J., Li, D., Xie, X., Yao, Y., Yan, L., Qin, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26677385
Novel tools for identification of oncogenic driver mutations
Chakroborty, D. (2023) · UTUPub (University of Turku)
ERBB4 as a potential therapeutic target in cancer
Ojala, V. (2024) · UTUPub (University of Turku) · Cited by 2
Rôle de GRASP-55 dans la spermatogenèse et la différenciation hématopoïétique
Bailly, A.-L. (2016) · theses.fr (ABES) · doi:10.70675/6a90ee09z2e30z436ez836cza01356b8ab98
Screening approaches for kinases
Chen, Y., & Xie, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43974-2.00014-8
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Cancers · doi:10.3390/cancers18091367
“Ba/F3 cells provide a well-established system for assessing oncogene dependency and inhibitor sensitivity, as their survival and proliferation are dependent on signaling from the introduced oncogenic driver [24].”
Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-51989-8
“Ba/F3 cells provide a well-established system for assessing kinase dependency and inhibitor sensitivity, as their survival and proliferation are strictly dependent on signaling from the introduced oncogenic driver kinase rather than endogenous growth factors 18 .”
Khosroyani, H. M., Teuber, A., Town, A., Klug, L. R., Evans, D., Call, J. W., Rothschild, S., Somaiah, N., Thirasastr, P., Liu, M., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0093
“First, we modeled mutations in Ba/F3 cells, a murine pro-B cell line that is a popular model system for studying oncogenic kinases (57).”
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-57463-9
“Ba/F3 cells were cultured and maintained as previously described for modeling oncogene addiction and kinase inhibitor sensitivity 42 .”
INVESTIGATING MONO-DRIVER VERSUS MULTI-DRIVER ONCOGENESIS VIA ALTERATIONS TO CELL SIGNALING PATHWAYS
Chapdelaine, A. G. (2025) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-4446
FAIRsharing record for: Drug Target Commons
FAIRsharing Team, & Tang, J. (2023) · FAIRsharing.org · doi:10.25504/fairsharing.2e2bb2
BindingDB Entry 50046393: Development of Selective Covalent Janus Kinase 3 Inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q2833tsh
BindingDB Entry 50016228: Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).
BindingDB (2023) · UC San Diego · doi:10.7270/q2bg2t07
BindingDB (2025) · UC San Diego · doi:10.7270/q2bg2tr3
BindingDB (2011) · UC San Diego · doi:10.7270/q2pg1rzp
BindingDB (2016) · UC San Diego · doi:10.7270/q29p3388
BindingDB Entry 50014374: Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-
BindingDB (2022) · UC San Diego · doi:10.7270/q23r0xp8
BindingDB Entry 50019842: Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q2fj2n6g
BindingDB Entry 50010404: Efficacy and Tolerability of Pyrazolo[1,5-
BindingDB (2021) · UC San Diego · doi:10.7270/q29s1vj7
BindingDB Entry 5958: Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer.
BindingDB (2013) · UC San Diego · doi:10.7270/q2v40svg
BindingDB (2012) · UC San Diego · doi:10.7270/q22n52pg
BindingDB Entry 50008580: Discovery of a potent dual ALK and EGFR T790M inhibitor.
BindingDB (2021) · UC San Diego · doi:10.7270/q2wh2tcg
BindingDB Entry 50031457: Selectively nonselective kinase inhibition: striking the right balance.
BindingDB (2010) · UC San Diego · doi:10.7270/q2vd6zk0
Assessment of the role of FGFR1-N546K mutations in neuroblastoma pathogenesis and treatment
Boland, J. (2026) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Synergy of Bosutinib and Chk-1 Inhibitor (PF) in Chemotherapy
Kolluri, A. (2014) · VCU Scholars Compass (Virginia Commonwealth University)
Roscoe, B. P. (2014) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2g027
Metadata
- Authors
- Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F.
- Affiliations
- Genomics Institute of the Novartis Research Foundation (US)
- Corresponding author
- Warmuth, Markus
- ORCID
- Xia, Gang
- Venue
- Current Opinion in Oncology
- Published
- 2007-01
- Volume
- 19
- Issue
- 1
- Pages
- 55-60
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2088757697
- Cited by
- 240
- References
- 60
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 27 · 2023: 22 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 5 · 2018: 13 · 2017: 14 · 2016: 14 · 2015: 9 · 2014: 11 · 2013: 10 · 2012: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ba/F3 cells, protein kinases, kinase inhibitors, kinase drug discovery, oncogenes, small-molecule kinase inhibitors, high-throughput screening, compound profiling, drug resistance prediction, point mutations, downstream signaling, interleukin-3 dependence
- MeSH terms
- Animals, Antineoplastic Agents, Cell Line, Cell Transformation, Neoplastic, Epidermal Growth Factor, Drug Design, Signal Transduction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.